New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Abstract
Estimating the probability of finding N2 or N3 (prN2/3) malignant nodal disease on EBUS-TBNA in patients with non-small cell lung cancer (NSCLC) can facilitate the selection of subsequent management strategies.The goal of this study was to develop a clinical prediction model for estimating the prN2/3.We used the AQuIRE registry to identify patients with NSCLC with clinical radiographic stage T1-3, N0-3, M0 disease that had EBUS-TBNA for staging. The dependent variable was the presence of N2 or N3 disease (vs. N0 or N1) as assessed by EBUS-TBNA. Univariate followed by multivariable logistic regression analysis was used to develop a parsimonious clinical prediction model to estimate prN2/3. External validation was performed using data from three other hospitals.The model derivation cohort (n=633) had a 25% prevalence of malignant N2 or N3 disease. Younger age, central location, adenocarcinoma histology, and higher PET-CT N stage were associated with a higher prN2/3. Area under the ROC curve was 0.85 (95% CI, 0.82-0.89), model fit was acceptable (Hosmer-Lemeshow p=0.62, Brier score 0.125). We externally validated the model in 722 patients. Area under the ROC curve was 0.88 (95% CI, 0.85-0.90). Calibration using the general calibration model method resulted in acceptable goodness of fit (Hosmer-Lemeshow test p=0.54, Brier score 0.132).Our prediction rule can be used to estimate prN2/3 in patients with NSCLC. The model has the potential to facilitate clinical decision making in the staging of NSCLC.
View details for DOI 10.1164/rccm.201607-1397OC
View details for PubMedID 28002683